Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human phase 1 studies

mAbs

Volumn 6, Issue 4, 2014, Pages 859-870

  Deslandes, Antoine ^a  

^a SANOFI   (France)

Author keywords

Antibody drug conjugates; Dose selection; Dosing regimen; Maximum tolerated dose; Oncology; Pharmacokinetics; Phase I

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; AVE 9633; BRENTUXIMAB VEDOTIN; BT 062; CALICHEAMICIN; CANTUZUMAB MERTANSINE; CANTUZUMAB RAVTANSINE; CYTOTOXIC AGENT; DCDS 4501A; DCDT 2980S; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB VEDOTIN; HUC 242DM 1; IMGN 388; IMGN 853; INOTUZUMAB OZOGAMICIN; LORVOTUZUMAB MERTANSINE; MEDI 547; MLN 0264; MLN 2704; MONOCLONAL ANTIBODY; SAR 3419; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; VORSETUZUMAB MAFODOTIN; ANTINEOPLASTIC AGENT; CANCER ANTIBODY;

AREA UNDER THE CURVE; CLINICAL EVALUATION; COMPARATIVE STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INDICATION; DRUG STRUCTURE; FIRST IN HUMAN STUDY; HEMATOLOGIC DISEASE; HUMAN; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; PHARMACODYNAMICS; PHARMACOKINETICS; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); REVIEW; SOLID TUMOR; FEMALE; MALE; METABOLISM; NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; NEOPLASMS;

EID: 84903759033     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.28965     Document Type: Review

References (34)

1. Gorovits B, Alley SC, Bilic S, Booth B, Kaur S, Oldfield P, Purushothama S, Rao C, Shord S, Siguenza P. Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper. Bioanalysis 2013; 5:997-1006; PMID:23641692; http://dx.doi.org/10.4155/bio.13.38
2. Mullard A. Maturing antibody-drug conjugate pipeline hits 30. Nat Rev Drug Discov 2013; 12:329-32; PMID:23629491; http://dx.doi.org/10.1038/nrd4009
3. Lapusan S, Vidriales MB, Thomas X, de Botton S, Vekhoff A, Tang R, Dumontet C, Morariu-Zamfir R, Lambert JM, Ozoux ML, et al. Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs 2012; 30:1121-31; PMID:21519855; http://dx.doi.org/10.1007/s10637-011-9670-0
4. Rowe JM, Löwenberg B. Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug. Blood 2013; 121:4838-41; PMID:23591788; http://dx.doi.org/10.1182/blood-2013-03-490482
5. Lu D, Joshi A, Wang B, Olsen S, Yi JH, Krop IE, Burris HA, Girish S. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer. Clin Pharmacokinet 2013; 52:657-72; PMID:23553425; http://dx.doi.org/10.1007/s40262- 013-0060-y
6. Pascual MH, Verdier P, Malette P, Mnich J, Ozoux ML. Validation of an immunoassay to selectively quantify the naked antibody of a new Antibody Drug Conjugate - SAR566658 - for pharmacokinetic interpretation improvement. J Immunol Methods 2013; 396:140-6; PMID:23892158; http://dx.doi.org/10.1016/j.jim. 2013.06.012
7. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:633-59; PMID:20818831; http://dx.doi.org/10.2165/11535960-000000000-00000
8. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93:2645-68; PMID:15389672; http://dx.doi.org/10.1002/jps.20178
9. EMA [Internet] Refusal assessment report for Mylotarg, Procedure No. EMEA/H/C/000705 2008 [Cited 2014 Feb 20] Available from http://www.ema.europa. eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/000705/ WC500070677.pdf
10. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49:493-507; PMID:20608753; http://dx.doi.org/10.2165/11531280-000000000-00000
11. Drugs@FDA:Kadcyla [Internet] Application Number: 125427orig1s000, Clinical Pharmacology and Biopharmaceutics Reviews [Cited 2014 Feb 20] Available from http://www.accessdata.fda.gov/drug-satfda-docs/nda/2013/ 125427Orig1s000ClinPharmR.pdf
12. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005; 56:361-9; PMID:15868146; http://dx.doi.org/10.1007/s00280-005-1026-z
13. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11:81-8; PMID:16478695; http://dx.doi.org/10.1016/S1359-6446(05)03638-X
14. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001; 41:1206-14; PMID:11697753; http://dx.doi.org/10.1177/ 00912700122012751
15. Drugs@FDA:Adcetris [Internet] Application Number: 125388Orig1s000, Clinical Pharmacology and Biopharmaceutics Reviews [Cited 2014 Feb 20] Available from http://www.accessdata.fda.gov/drug-satfda-docs/nda/2011/ 125388Orig1s000ClinPha rmR.pdf
16. Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, Burris Iii HA, LoRusso PM, Yi JH, Saad O, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012; 69:1229-40; PMID:22271209; http://dx.doi.org/10.1007/s00280-011-1817-3
17. Ferte C, Soria JC, Penel N. Dose-levels and first signs of efficacy in contemporary oncology Phase 1 clinical trials. PLoS One 2011; 6:e16633; PMID:21415927; http://dx.doi.org/10.1371/journal.pone.0016633
18. Roberts SA, Andrews PA, Blanset D, Flagella KM, Gorovits B, Lynch CM, Martin PL, Kramer-Stickland K, Thibault S, Warner G. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology. Regul Toxicol Pharmacol 2013; 67:382-91; PMID:24012707; http://dx.doi.org/10.1016/j. yrtph.2013.08.017
19. Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R. Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs 2013; 31:77-84; PMID:22370972; http://dx.doi.org/10.1007/s10637-012-9801-2
20. Haddish-Berhane N, Shah DK, Ma D, Leal M, Gerber HP, Sapra P, Barton HA, Betts AM. On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J Pharmacokinet Pharmacodyn 2013; 40:557-71; PMID:23933716; http://dx.doi.org/10.1007/s10928-013-9329-x
21. Coiffier B, Morschhauser F, Dupuis J, Haioun C, Laine F, Houot R, et al. Phase I study cohort evaluating an optimized administration schedule of SAR3419, an anti-CD19 DM4-loaded antibody drug conjugate (ADC), in patients (pts) with CD19 positive relapsed/refractory b-cell non-Hodgkin's lymphoma. J Clin Oncol 2012; 30(Suppl. 1):8057
22. Castaigne S, Pautas C, Terré C, Raffoux E, Bordessoule D, Bastie JN, Legrand O, Thomas X, Turlure P, Reman O, et al.; Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379:1508-16; PMID:22482940; http://dx.doi.org/10.1016/S0140- 6736(12)60485-1
23. Sapra P, Betts A, Boni J. Preclinical and clinical pharmacokinetic/ pharmacodynamic considerations for antibody-drug conjugates. Expert Rev Clin Pharmacol 2013; 6:541-55; PMID:23978126; http://dx.doi.org/10.1586/17512433. 2013.827405
24. Food and Drug Administration Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, U.S. Department of Health and Human Services,, Center for Drug Evaluation and Research (CDER), July 2005
25. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Rohatiner A, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010; 28:2085-93; PMID:20308665; http://dx.doi.org/10.1200/JCO.2009.25.1900
26. Chanan-Khan A, Wolf JL, Garcia J, Gharibo M, Jagannath S, Manfredi D, et al. Efficacy analysis from phase I study of lorvotuzumab mertansine (IMGN901), used as monotherapy, in patients with heavily pre-treated CD56-positive multiple myeloma - A preliminary efficacy analysis. Blood 2010; 116:21
27. Chanan-Khan AA, Jagannath S, Heffner LT, Avigan D, Lee KP, Lutz RJ, et al. Phase I study of BT062 given as repeated single dose once every 3 weeks in patients with relapsed or relapsed/refractory multiple myeloma. Blood 2009; 114:22
28. Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A, Lee Y, Webb IJ, Scher HI. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 2008; 26:2147-54; PMID:18362364; http://dx.doi.org/10.1200/JCO.2007.15.0532
29. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28:2698-704; PMID:20421541; http://dx.doi.org/10.1200/JCO.2009.26.2071
30. Petrylak DP, Kantoff PW, Mega AE, Vogelzang NJ, Stephenson J, Fleming MT, Stambler N, Petrini M, Blattman S, Israel RJ. Prostate- specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane. J Clin Oncol 2013; 31(Suppl. 1)
31. Sauter A, Kloft C, Gronau S, Bogeschdorfer F, Erhardt T, Golze W, Schroen C, Staab A, Riechelmann H, Hoermann K. Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol 2007; 30:927-35; PMID:17332932
32. Sznol M, Hamid O, Hwu P, Kluger H, Hawthorne T, Crowley E, et al. Pharmacokinetics (PK) of CR011-vcMMAE, an antibody-drug conjugate (ADC), in a phase (Ph) I study of patients (pts) with advanced melanoma. J Clin Oncol 2009; 27(Suppl.1):9063
33. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003; 21:211-22; PMID:12525512; http://dx.doi.org/10.1200/JCO.2003.05.137
34. Younes A, Kim S, Romaguera J, Copeland A, Farial SdeC, Kwak LW, Fayad L, Hagemeister F, Fanale M, Neelapu S, et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. J Clin Oncol 2012; 30:2776-82; PMID:22753910; http://dx.doi.org/10.1200/JCO.2011. 39.4403